Volume 124, Issue 1, Pages (January 2012)

Slides:

Advertisements

Similar presentations

Advances and Emerging Therapy for Lung Cancer

Advertisements

Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.

A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Volume 64, Pages e1-e3 (January 2017)

Trine Grantzau, Mette Skovhus Thomsen, Michael Væth, Jens Overgaard

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Alzheimer's disease drug development pipeline: 2018

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Volume 145, Issue 2, Pages (May 2017)

Volume 138, Issue 1, Pages (July 2015)

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Volume 141, Issue 2, Pages (May 2016)

Volume 130, Issue 3, Pages (September 2013)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 148, Issue 1, Pages (January 2018)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia S.-C. Kuo, Y.-T. Lee,

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Superior sulcus (Pancoast) tumor: experience with 105 patients

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Long-Term Hormonal Therapy: Who Would Benefit?

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

ORAL SESSIONS Journal of Thoracic Oncology

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 14, Issue 6, Pages (May 2013)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Adjuvant Chemotherapy Is Associated with Improved Survival after Esophagectomy without Induction Therapy for Node-Positive Adenocarcinoma Paul J. Speicher,

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

RTOG 0017: A Phase I Trial of Concurrent Gemcitabine/Carboplatin or Gemcitabine/Paclitaxel and Radiation Therapy (“Ping-Pong Trial”) Followed By Adjuvant.

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Volume 147, Issue 3, Pages (December 2017)

Benny Weksler, MD, Manisha Shende, MD, Katie S

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 115, Issue 1, Pages (October 2009)

Volume 153, Issue 3, Pages (June 2019)

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 124, Issue 1, Pages 26-30 (January 2012) Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma Mark H. Einstein, Merieme Klobocista, June Y. Hou, Stephen Lee, Subhakar Mutyala, Keyur Mehta, Laura L. Reimers, Dennis Y.-S. Kuo, Gloria S. Huang, Gary L. Goldberg Gynecologic Oncology Volume 124, Issue 1, Pages 26-30 (January 2012) DOI: 10.1016/j.ygyno.2011.10.008 Copyright © 2011 Terms and Conditions

Fig. 1 Treatment numbers on protocol. Toxicity analysis performed on the 27 patients who received at least one dose of chemotherapy. Survival analysis was performed in all patients who received the first 3 cycles of chemotherapy followed by RT. Gynecologic Oncology 2012 124, 26-30DOI: (10.1016/j.ygyno.2011.10.008) Copyright © 2011 Terms and Conditions

Fig. 2 Kaplan–Meier survival curve of early stage (stage I and II) and late stage (stage III and IV) uterine CS patients treated with radiation “sandwiched” between three cycles of cisplatin/ifosfamide or ifosfamide chemotherapy before and after RT. 2-year DFS for early stage patients was 18.07±1.21 (mean±standard error) months and for advanced stage patients was 15.72±1.79months. Gynecologic Oncology 2012 124, 26-30DOI: (10.1016/j.ygyno.2011.10.008) Copyright © 2011 Terms and Conditions